Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:administered_by |
injection
|
| gptkbp:available_on |
gptkb:Software_Solutions
gptkb:tablet injection solution |
| gptkbp:brand |
gptkb:Fusilev
gptkb:Leucovorin_Calcium gptkb:Wellcovorin |
| gptkbp:casnumber |
58-05-9
|
| gptkbp:chemical_formula |
C20 H24 N8 O7 S
|
| gptkbp:clinical_trial |
studied for use in combination therapies
studied for use in high-dose methotrexate regimens studied for use in pediatric oncology studied for use in various cancers |
| gptkbp:clinical_use |
enhancing efficacy of fluorouracil
preventing methotrexate toxicity |
| gptkbp:composed_by |
gptkb:chemical_compound
extraction from natural sources |
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to leucovorin |
| gptkbp:developed_by |
folic acid
|
| gptkbp:discovered_by |
1950s
|
| gptkbp:dissolved |
water-soluble
|
| https://www.w3.org/2000/01/rdf-schema#label |
leucovorin
|
| gptkbp:interacts_with |
gptkb:methotrexate
gptkb:fluorouracil other folate antagonists |
| gptkbp:known_as |
folinic acid
|
| gptkbp:mechanism_of_action |
reduces toxicity of methotrexate
|
| gptkbp:pharmacokinetics |
excreted in urine
rapidly absorbed acts as a cofactor in DNA synthesis widely distributed in tissues |
| gptkbp:research_areas |
toxicology
oncology pharmacology clinical pharmacology |
| gptkbp:route_of_administration |
oral
intravenous |
| gptkbp:safety |
generally well tolerated
FDA pregnancy category A |
| gptkbp:side_effect |
nausea
allergic reactions diarrhea |
| gptkbp:targets |
gptkb:Oncology
ovarian cancer |
| gptkbp:used_in |
gptkb:cancer_treatment
methotrexate rescue |
| gptkbp:weight |
458.5 g/mol
|
| gptkbp:bfsParent |
gptkb:methotrexate
|
| gptkbp:bfsLayer |
5
|